Please login to the form below

Not currently logged in
Email:
Password:

Lamzede

This page shows the latest Lamzede news and features for those working in and with pharma, biotech and healthcare.

Chiesi launches new rare disease R&D division

Chiesi launches new rare disease R&D division

Chiesi already markets rare disease therapy Lamzede (velmanase alfa), which is approved by the European Medicines Agency for the treatment of patients with mild to moderate alpha-mannosidosis. ... Chiesi acquired Lamzede when it bought Zymenex in 2013

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....